.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Moodys
Cipla
Chinese Patent Office
Accenture
Boehringer Ingelheim
Daiichi Sankyo
Farmers Insurance
QuintilesIMS
Cantor Fitzgerald

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,403,120

« Back to Dashboard

Which drugs does patent 6,403,120 protect, and when does it expire?


Patent 6,403,120 protects VENLAFAXINE HYDROCHLORIDE and EFFEXOR XR and is included in two NDAs. There has been one Paragraph IV challenge on Effexor XR.

Protection for EFFEXOR XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eighty-seven patent family members in forty-four countries.

Summary for Patent: 6,403,120

Title: Extended release formulation of venlafaxine hydrochloride
Abstract:This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and fiber provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.
Inventor(s): Sherman; Deborah M. (Plattsburgh, NY), Clark; John C. (Peru, NY), Lamer; John U. (St. Albans, VT), White; Steven A. (Champlain, NY)
Assignee: Wyeth (Madison, NJ)
Application Number:09/950,965
Patent Claim Types:
see list of patent claims
Use; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Osmotica PharmVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022104-001May 20, 2008ABRXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Osmotica PharmVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022104-001May 20, 2008ABRXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF SOCIAL ANXIETY DISORDER
Osmotica PharmVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022104-002May 20, 2008ABRXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF SOCIAL ANXIETY DISORDER
Osmotica PharmVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022104-002May 20, 2008ABRXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Osmotica PharmVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022104-003May 20, 2008ABRXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF SOCIAL ANXIETY DISORDER
Osmotica PharmVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022104-003May 20, 2008ABRXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Osmotica PharmVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022104-004May 20, 2008ABRXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF SOCIAL ANXIETY DISORDER
Osmotica PharmVENLAFAXINE HYDROCHLORIDEvenlafaxine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022104-004May 20, 2008ABRXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Wyeth Pharms IncEFFEXOR XRvenlafaxine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL020699-001Oct 20, 1997ABRXYesNo► Subscribe► Subscribe► SubscribeY
Wyeth Pharms IncEFFEXOR XRvenlafaxine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL020699-002Oct 20, 1997ABRXYesNo► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,403,120

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,274,171 Extended release formulation of venlafaxine hydrochloride► Subscribe
6,419,958 Extended release formulation of venlafaxine hydrochloride► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,403,120

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina006519► Subscribe
Argentina014012► Subscribe
Austria237320► Subscribe
Austria257011► Subscribe
Australia1300399► Subscribe
Australia1640097► Subscribe
Australia727653► Subscribe
Australia747978► Subscribe
Bulgaria104397► Subscribe
Brazil9701304► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Julphar
Accenture
Fish and Richardson
Chinese Patent Office
Teva
Mallinckrodt
Dow
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot